#healthcare #Israel #OncoHost #PROphet #Binyamina

OncoHost Takes Center Stage at the 2025 Merit Awards

OncoHost, a bold leader in precision oncology, proudly announced it has secured the prestigious title of Gold Winner at the 2025 Merit Awards for Healthcare. This award signifies the recognition of their groundbreaking technology, the PROphet® platform, designed to transform cancer care through advanced proteomics and artificial intelligence (AI).

Innovating Cancer Care

In a world where healthcare technology rapidly evolves, OncoHost is pioneering a new paradigm. The company's PROphet® platform is an AI-driven solution that analyzes blood samples to predict how patients will respond to cancer therapies. This innovative approach focuses on individual patient profiles, providing oncologists with critical insights to guide effective treatment options right from the start. According to Ofer Sharon, MD, CEO of OncoHost, this distinction showcases the substantial clinical importance of their technology in oncology.

The Science Behind PROphet®

What sets the PROphet® platform apart? It employs proprietary machine-learning algorithms to assess over 7,000 proteins in a patient's plasma. This data enables the generation of personalized predictive models that inform about overall and progression-free survival, which is paramount for oncologists in making informed treatment decisions.

OncoHost's initial offering, the PROphetNSCLC®, stands alone as the only AI-based blood test currently available that forecasts patient outcomes in stage one immunotherapy for metastatic non-small cell lung cancer (NSCLC).

The company is not stopping there. Plans for launching additional products, including PROphetRCC™ and PROphetMELANOMA™, are underway. These tools will further support clinical decision-making across various tumor types. A remarkable addition to the PROphet lineup is the PROphetirAE™, aimed at predicting severe immune-related adverse events prior to therapy initiation.

A Milestone Achievement

This accolade marks a significant milestone for OncoHost, indicating their growing influence within the U.S. healthcare landscape. With increasing collaborations on a global scale and acceptance into prominent scientific conferences, OncoHost is successfully showcasing the advantages of its innovative platform, emphasizing its leadership in the field of host-response biomarker innovation.

The Merit Awards for Healthcare serve to honor organizations that are making a meaningful difference in patient care through innovative technologies. OncoHost’s impressive performance in this competitive space epitomizes their commitment to providing oncology professionals with tools that enhance patient outcomes.

The Road Ahead

OncoHost, headquartered in Binyamina, Israel, and Cary, North Carolina, is poised to lead the charge in precision medicine. Their approach to utilizing plasma-based, proteomic pattern analysis continues to evolve, reflecting the changing needs of the oncology field. The team is dedicated to developing solutions that empower healthcare providers to deliver personalized treatment plans, ultimately improving survival rates among cancer patients.

As they bask in the glow of their recent award, OncoHost remains focused on innovation and the improvement of patient health worldwide. For ongoing developments and insights into their pioneering work, follow OncoHost on their social media platforms, including LinkedIn, Twitter, Facebook, and YouTube.

In conclusion, OncoHost's recognition as a Gold Winner at the 2025 Merit Awards for Healthcare exemplifies their trailblazing work in precision oncology and serves as an inspiration for those in the healthcare technology arena. It solidifies their mission to redefine cancer treatment through unprecedented scientific advancements.